Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
This review summarizes the complex and contradictory evidence regarding Lipoprotein (a) as a risk factor for ischaemic stroke and discusses potential mechanisms and therapies.
Strokes are one of the most common causes of mortality and long term severe disability. There is evidence that lipoprotein (a) (Lp(a)) is a predictor of many forms of vascular disease, including premature coronary artery disease. Several studies have also evaluated the association between Lp(a) and ischaemic (thrombotic) stroke. Several cross sectional (and a few prospective) studies provide contradictory findings regarding Lp(a) as a predictor of ischaemic stroke. Several factors might contribute to the existing confusion--for example, small sample sizes, different ethnic groups, the influence of oestrogens in women participating in the studies, plasma storage before Lp(a) determination, statistical errors, and selection bias. This review focuses on the Lp(a) related mechanisms that might contribute to the pathogenesis of ischaemic stroke. The association between Lp(a) and other cardiovascular risk factors is discussed. Therapeutic interventions that can lower the circulating concentrations of Lp(a) and thus possibly reduce the risk of stroke are also considered.
No takes yet. Share an insight, caveat, or question.
A 2000 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: